UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) September 8, 2004
-----------------
Impax Laboratories, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-27354 65-0403311
- --------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
30381 Huntwood Avenue Hayward, CA 94544
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(510) 476-2000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 - REGULATION FD DISCLOSURE
On September 8, 2004, Impax Laboratories, Inc. (the "Company") issued a
press release announcing that its Omeprazole Delayed Release Capsules 20mg have
been commercially launched by the Company and Teva Pharmaceutical Industries
Ltd. A copy of the press release is attached as Exhibit 99.1 and is incorporated
herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: September 8, 2004
By: /s/ Cornel C. Spiegler
---------------------------
Cornel C. Spiegler
Chief Financial Officer